Overview
LUYE PHARMA (2186)
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the Un...
- Open
- 1.580
- High
- 1.580
- Low
- 1.535
- Prev. Close
- 1.570
- Volume
- 23.75M
- Turnover
- 36.82M
- Avg Price
- 1.550
- Bid/Ask Ratio
- -91.27%
- Amplitude
- 2.87%
- 52wk High
- 3.250
- Volume Ratio
- 0.50
- Turnover Ratio
- 0.59%
- 52wk Low
- 1.535
- HK Mkt Cap
- 6.17B
- Market CapHKD
- 6.17B
- P/ETTM
- 7.70
- P/EDynamic
- 6.86
- P/EStatic
- --
- EPSTTM
- 0.201
- EPSDynamic
- 0.225
- EPSStatic
- --
- BVPS
- 4.42
- P/B
- 0.35
- HK Shares
- 3.99B
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 3.99B
- Min lot size
- 500
- Currency
- HKD
LUYE PHARMA Analyst Rating
View moreForecast & Rating
Oct 8, 2026- Strong buy50.00%
- Buy0.00%
- Hold50.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 1
- Buy
- 0
- Hold
- 1
- Sell
- 0
- Strong sell
- 0
Daily Events
- Jul, 3
Luye Pharma surged 9.14% to close at HKD 2.030 on heavy volume, driven by positive Phase II top-line results for LY03015 in tardive dyskinesia (TD). The drug showed significant improvement in LSM at week 24 with a rapid onset by week 6 and a favorable safety profile. The stock opened low at HKD 1.870 and rallied steadily to hit intraday high of HKD 2.030 in the afternoon session, with turnover exceeding HKD 200 million. Financially, net profit surged over 200% YoY in Q3-Q4, while EPS improved to HKD 0.0422, though revenue growth remained single-digit. The price reclaimed the 20-day MA (HKD 1.877), yet YTD declines of 26.71% and a 54.79% gap from the 52-week high of HKD 4.49 persist, with a PB of 0.47x. However, the 60-day MA (HKD 2.328) still looms as overhead resistance.
